-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent news, the emerging Internet giant ByteDance has entered a major track in the pharmaceutical industry-AI pharmaceuticals
.
The Tianyan Check App shows that the drug R&D start-up "Shuimu Future (Beijing) Technology Co.
, Ltd.
" has recently undergone business changes, and Beijing Quantum Jump Technology Co.
, Ltd.
, which is wholly-owned by Bytedance, has been added to the list of shareholders
.
Prior to this, the industry also reported that ByteDance’s three R&D teams were recruiting talents in the AI pharmaceutical field
.
In fact, in addition to Bytedance, companies such as Tencent and Baidu have already set foot in the field of AI pharmaceuticals
.
For example, Tencent launched the AI drug discovery platform "Yunshen Pharmaceutical" in July 2020, and Baidu established the life science platform "Baitu Shengke" in September 2020; Huawei also announced the recruitment of drug development algorithm engineers last year.
.
So, behind the Internet technology giants have cross-bordered into the AI pharmaceutical field, how dazzling is this field? According to the industry, traditional biopharmaceutical companies have pain points such as long research and development cycles, high failure rates, and high costs when conducting new drug research and development.
The reason why AI pharmaceuticals is so popular is that it can solve the pain points of artificial pharmaceuticals to a certain extent, including improving the development of new drugs.
Success rate, reduce related costs and time in the pharmaceutical process, and bring huge returns to the enterprise
.
The industry is generally optimistic about the application prospects of artificial intelligence in the field of biomedicine
.
It is reported that from early drug discovery to prescription treatment options, the use of AI in the biopharmaceutical industry is steadily expanding.
By 2024, the industry’s market capacity is expected to reach one billion US dollars (including AI-based medical imaging, diagnosis, and personal AI assistants.
, Drug Discovery and Genomics)
.
As the giants get together to lay out the AI pharmaceutical track, capital has continued to increase
.
Relevant data shows that in 2020 alone, the number of financing projects in the AI pharmaceutical field has almost doubled, and the total financing this year has also surged from 242 million yuan in 2019 to 2.
723 billion yuan
.
Among them, Jingtai Technology received a financing of 300 million US dollars in September 2020.
There are many large enterprises and institutions such as Google, Softbank, Morningstar, CICC, Sequoia, etc.
.
It is worth mentioning that although the prospects for AI pharmaceuticals are good, there are also pain points that need to be overcome, such as the problem of drug synthesis.
Some analysts have pointed out that the key to solving this problem lies in data, but the current lack of data is a major obstacle
.
With the continuous improvement of data and the continuous optimization and improvement of AI models, its huge driving force in drug synthesis in the future will be further revealed
.
In addition, the lack of talents is also a "blocker" in the development of the AI pharmaceutical industry
.
As AI pharmacy is a multidisciplinary industry, it requires the collaborative innovation of information technology talents and biopharmaceutical talents, but the scarcity of talents is a major pain point
.
The industry believes that in the future, AI pharmaceutical companies will reserve talents with backgrounds in computational biology, computational chemistry, and AI algorithm design required for calculations on the one hand, and will also introduce pharmacy, drug clinical trials and clinical trials extensively on the other hand.
Talents in medicine and other fields
.
At the same time, talents with a combined background in algorithm and drug development have become scarce resources in the market
.
Generally speaking, although China's AI pharmaceutical development seems to be in full swing, it is only in its infancy stage, and there is still a long way to go in the future
.
.
The Tianyan Check App shows that the drug R&D start-up "Shuimu Future (Beijing) Technology Co.
, Ltd.
" has recently undergone business changes, and Beijing Quantum Jump Technology Co.
, Ltd.
, which is wholly-owned by Bytedance, has been added to the list of shareholders
.
Prior to this, the industry also reported that ByteDance’s three R&D teams were recruiting talents in the AI pharmaceutical field
.
In fact, in addition to Bytedance, companies such as Tencent and Baidu have already set foot in the field of AI pharmaceuticals
.
For example, Tencent launched the AI drug discovery platform "Yunshen Pharmaceutical" in July 2020, and Baidu established the life science platform "Baitu Shengke" in September 2020; Huawei also announced the recruitment of drug development algorithm engineers last year.
.
So, behind the Internet technology giants have cross-bordered into the AI pharmaceutical field, how dazzling is this field? According to the industry, traditional biopharmaceutical companies have pain points such as long research and development cycles, high failure rates, and high costs when conducting new drug research and development.
The reason why AI pharmaceuticals is so popular is that it can solve the pain points of artificial pharmaceuticals to a certain extent, including improving the development of new drugs.
Success rate, reduce related costs and time in the pharmaceutical process, and bring huge returns to the enterprise
.
The industry is generally optimistic about the application prospects of artificial intelligence in the field of biomedicine
.
It is reported that from early drug discovery to prescription treatment options, the use of AI in the biopharmaceutical industry is steadily expanding.
By 2024, the industry’s market capacity is expected to reach one billion US dollars (including AI-based medical imaging, diagnosis, and personal AI assistants.
, Drug Discovery and Genomics)
.
As the giants get together to lay out the AI pharmaceutical track, capital has continued to increase
.
Relevant data shows that in 2020 alone, the number of financing projects in the AI pharmaceutical field has almost doubled, and the total financing this year has also surged from 242 million yuan in 2019 to 2.
723 billion yuan
.
Among them, Jingtai Technology received a financing of 300 million US dollars in September 2020.
There are many large enterprises and institutions such as Google, Softbank, Morningstar, CICC, Sequoia, etc.
.
It is worth mentioning that although the prospects for AI pharmaceuticals are good, there are also pain points that need to be overcome, such as the problem of drug synthesis.
Some analysts have pointed out that the key to solving this problem lies in data, but the current lack of data is a major obstacle
.
With the continuous improvement of data and the continuous optimization and improvement of AI models, its huge driving force in drug synthesis in the future will be further revealed
.
In addition, the lack of talents is also a "blocker" in the development of the AI pharmaceutical industry
.
As AI pharmacy is a multidisciplinary industry, it requires the collaborative innovation of information technology talents and biopharmaceutical talents, but the scarcity of talents is a major pain point
.
The industry believes that in the future, AI pharmaceutical companies will reserve talents with backgrounds in computational biology, computational chemistry, and AI algorithm design required for calculations on the one hand, and will also introduce pharmacy, drug clinical trials and clinical trials extensively on the other hand.
Talents in medicine and other fields
.
At the same time, talents with a combined background in algorithm and drug development have become scarce resources in the market
.
Generally speaking, although China's AI pharmaceutical development seems to be in full swing, it is only in its infancy stage, and there is still a long way to go in the future
.
